Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.

By B. de Bruyne, N. Pijls, B. Kalesan, E. Barbato, P. Tonino, Z. Piróth, N. Jagic, S. Möbius‐Winkler, G. Rioufol, N. Witt and 12 more. New England Journal of Medicine, 2012

2,461 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/3cd6b0fde371e0dd908038944f6ae5a42778b6dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Charles A. Taylor
2. T. Fonte
3. B. Nørgaard
4. James K. Min
5. J. Leipsic
6. B. Koo
7. S. Gaur
8. A. Erglis

Citations in the corpus

• Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). (2014, background): “80 distinguishes patients and coronary lesions that will benefit from coronary revascularization (7) from those that will not (8).”
• Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes. (2014, methodology): “The ongoing FAME-2 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation-2) trial (5) randomized 441 patients to initial medical therapy with 625 lesions having FFR #0.”
• Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve: scientific basis. (2013, methodology): “In the FAME2 trial, FFR-guided therapy reduced the need for urgent revascularization in patients with stable CAD and hemodynamically significant lesions (10).”